Phathom Pharmaceuticals (PHAT)
(Delayed Data from NSDQ)
$18.30 USD
-1.20 (-6.15%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $18.29 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Phathom Pharmaceuticals, Inc. [PHAT]
Reports for Purchase
Showing records 1 - 10 ( 10 total )
Company: Phathom Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Voquezna?s Early Launch in Broad GERD; Heartburn?s Days Are Numbered; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Phathom Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Broad GERD Market Now in Play-Initial Thoughts on Voquezna Approval in Non-Erosive GERD
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Phathom Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Voquezna GERD Launch Success With Near-Term PDUFA Opportunity; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Phathom Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Voquezna in Erosive GERD Off to the Races-Non-Erosive GERD Near-Term PDUFA; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Phathom Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Near-Term Combined Launch in Erosive GERD and H. Pylori Assert Voquezna; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Phathom Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Voquezna FDA Approval Sets New Stage in Erosive GERD and Beyond-First Innovation in Decades; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Phathom Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Vonoprazan Stability-Looking to November PDUFA, Potential 4Q23 Launch; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Phathom Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Novel GERD Therapy With Potential Commercial Launches 4Q23; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Phathom Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Novel PCAB Approach Turns New Page for GERD Therapy; Initiating With Buy Rating and $28 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Phathom Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
|